share_log

翰森製藥:截至二零二四年三月三十一日止月份之股份發行人的證券變動月報表

HANSOH PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 2 06:10
Summary by Moomoo AI
翰森制药集团有限公司於2024年4月2日向香港交易及结算所有限公司提交了最新的证券变动月报表,涵盖截至2024年3月31日的信息。报表显示,公司的法定/注册股本及已发行股份在报告期内均无变动,法定/注册股本维持在200,000港元,而已发行股份总数保持在5,933,350,070股。此外,公司确认在报告期内没有发行新证券,且所有相关的上市规则要求和法律规定均已遵守。报表由联席公司秘书钟胜利女士呈交。
翰森制药集团有限公司於2024年4月2日向香港交易及结算所有限公司提交了最新的证券变动月报表,涵盖截至2024年3月31日的信息。报表显示,公司的法定/注册股本及已发行股份在报告期内均无变动,法定/注册股本维持在200,000港元,而已发行股份总数保持在5,933,350,070股。此外,公司确认在报告期内没有发行新证券,且所有相关的上市规则要求和法律规定均已遵守。报表由联席公司秘书钟胜利女士呈交。
Hansen Pharmaceutical Group Limited filed with Hong Kong Trading and Settlement Limited on 2 April 2024 with Hong Kong Trading and Settlement Limited, covering information as of 31 March 2024. The report shows that the company's regulary/registered capital and issued shares remained unchanged during the reporting period, with the regulated/registered share capital remaining at HK$200,000 and the total issued shares at 5,933,350,070 shares. In addition, the Company confirms that no new securities were issued during the reporting period and that all relevant listing rules requirements and legal regulations have been complied with. The report was presented by the Joint Secretary of the Joint Undertaking, Ms. Chung Cheng.
Hansen Pharmaceutical Group Limited filed with Hong Kong Trading and Settlement Limited on 2 April 2024 with Hong Kong Trading and Settlement Limited, covering information as of 31 March 2024. The report shows that the company's regulary/registered capital and issued shares remained unchanged during the reporting period, with the regulated/registered share capital remaining at HK$200,000 and the total issued shares at 5,933,350,070 shares. In addition, the Company confirms that no new securities were issued during the reporting period and that all relevant listing rules requirements and legal regulations have been complied with. The report was presented by the Joint Secretary of the Joint Undertaking, Ms. Chung Cheng.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more